Correlation Between Prolactin and Symptom Profile in Acute Admitted Women With Recurrent Schizophrenia

Herceg, Miroslav; Puljić, Krešimir; Sakoman, Andrea Jambrošić; Sušac, Jelena; Laidlaw, Ivana Todorić; Herceg, Dora; Sisek-Šprem, Mirna

doi:10.24869/psyd.2020.367

Cited by 6 publications

(5 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Riecher-Rössler [21] implicates (perhaps stress-induced) high prolactin levels leading to oestrogen and testosterone decline in triggering psychotic symptoms. Thomas and collaborators [22] carried out a 12week follow-up study of 45 women with schizophrenia whose mean age was 46. This study explored the association between psychotic and depressive symptoms, and hormonal levels of oestradiol, progesterone, follicular stimulating hormone (FSH), luteinising hormone (LH), and dehydroepiandrosterone (DHEA).…”

Section: The Oestrogen Protection Hypothesis Of Schizophreniamentioning

confidence: 99%

“…Using the Positive and Negative Syndrome Scale (PANSS), they identified two trajectories for psychotic symptoms: 1) lower symptom severity associated with FSH, LH, and DHEA, and 2) higher symptom severity associated with LH. This paper highlights the fact that reproductive hormones play a role in the pathophysiology of schizophrenia and recommends stratification of patients according to endocrine variables [22].…”

Section: The Oestrogen Protection Hypothesis Of Schizophreniamentioning

confidence: 99%

See 1 more Smart Citation

Improving treatment of women with schizophrenia: a review of the recent literature

González-Rodríguez,

Cobo,

Seeman

2023

Exploration of Medicine

View full text Add to dashboard Cite

Effective clinical management of women with schizophrenia is therapeutically challenging. While there have been recent advances in the understanding of neurobiological, hormonal, and female reproductive cycle factors that play a decisive role in the development and progression of schizophrenia in women, this knowledge has not yet been fully translated into treatment practice. The aim was to apply the best evidence available to optimally treat women with schizophrenia at various periods of the lifespan. A narrative review was conducted of recent advances (2018–2023) in aspects of schizophrenia in women that demand sex-specific treatment. Sex steroids impact antipsychotic absorption, distribution, metabolism, elimination, passage through the blood-brain barrier, and blood flow rate to the brain. For these reasons, premenopausal women with schizophrenia, as compared to male age peers, require lower doses of most antipsychotic drugs and suffer comparatively more adverse events (metabolic, sexual, and cardiovascular) at similar doses. Apart from pharmacologic treatment, women have specific reproductive planning needs and need protection from sexual exploitation and domestic abuse. In addition, when pregnant, schizophrenia women show a high risk of gestational diabetes and pre-eclampsia/eclampsia that requires prevention. Prevention is also needed against long-term health hazards for their offspring. Another period of therapeutic challenge specific to women is menopause. The collected evidence points to women-specific recommendations for both biological and psychosocial treatment strategies for schizophrenia.

show abstract

Section: The Oestrogen Protection Hypothesis Of Schizophreniamentioning

confidence: 99%

Section: The Oestrogen Protection Hypothesis Of Schizophreniamentioning

confidence: 99%

Improving treatment of women with schizophrenia: a review of the recent literature

González-Rodríguez,

Cobo,

Seeman

2023

Exploration of Medicine

View full text Add to dashboard Cite

show abstract

“…The patients examined presented patterns of positive psychotic symptoms (including bewildering auditory hallucinations and reference delusions) occurring only in the last week of the luteal phase and resolving within a few days after menses 24 . It is hypothesised that reproductive hormones, especially estradiol, may affect a course of psychotic disorders 25 , 26 and a significant increase in admission to the psychiatric hospital due to psychosis during the perimenstrual phase was observed in some studies 25 , 26 and confirmed in a meta-analysis 27 . The hypothesised mechanism of that phenomenon is estradiol withdrawal in the perimenstrual phase, as estrogens seem to have a protective role against psychosis (but other reproductive hormones may also play a role) 26 .…”

Section: Introductionmentioning

confidence: 99%

Depression and anxiety mediate the relationship between the retrospectively measured symptoms of premenstrual disorders and negative but not positive psychotic-like experiences

Antosz-Rekucka,

Prochwicz

2023

Sci Rep

View full text Add to dashboard Cite

The aim of this study was to examine the relationship between retrospectively measured premenstrual symptoms and subclinical forms of positive and negative psychotic symptoms (psychotic-like experiences; PLEs). It was hypothesised that subjective intensity of the symptoms of premenstrual disorders predicts PLEs frequency and that this relationship is mediated by anxiety and depression. The study sample comprised 108 non-clinical subjects. Study variables were assessed with self-report questionnaires: the Premenstrual Symptoms Screening Tool (PSST); the Beck Depression Inventory Second Edition (BDI-II); the State-Trait Anxiety Inventory (STAI; trait sub-scale); the Community Assessment of Psychic Experiences (CAPE). Regression and mediation analyses were performed. The PSST scores were significantly and positively associated with psychotic-like experiences frequency. The relation was stronger for positive PLEs. Anxiety and depression partially mediated the relationship between premenstrual symptoms and negative PLEs, but not between premenstrual symptoms and positive PLEs. Although the design of the study does not allow to infer causality, it demonstrates strong, positive relationship between the symptoms of premenstrual disorders and psychotic-like experiences. The relationship between premenstrual disorders and negative PLEs seems to be partially based on a general psychopathological factor. Further longitudinal studies are needed to test whether premenstrual disturbances increase risk of psychotic symptoms.

show abstract

“…The prevalence of hyperprolactinaemia among patients with schizophrenia on antipsychotic medications has been estimated to range between 30% and 75%. 12 , 13 , 14 It is more frequent among women than men even among drug-naïve first-episode psychosis patients, higher doses of medications, greater severity of illness on the Positive and Negative Symptoms Scale (PANSS) or Brief Psychiatric Rating Scale (BPRS) and the newly initiated on antipsychotics. 14 , 15 , 16 Hyperprolactinaemia has also been observed to be significantly higher in drug-naïve patients than in healthy controls.…”

Section: Introductionmentioning

confidence: 99%

“… 12 , 13 , 14 It is more frequent among women than men even among drug-naïve first-episode psychosis patients, higher doses of medications, greater severity of illness on the Positive and Negative Symptoms Scale (PANSS) or Brief Psychiatric Rating Scale (BPRS) and the newly initiated on antipsychotics. 14 , 15 , 16 Hyperprolactinaemia has also been observed to be significantly higher in drug-naïve patients than in healthy controls. 17 , 18 Hyperprolactinaemia may be asymptomatic in some patients and the most common symptoms of chronic hyperprolactinemia are reproductive dysfunction (anovulatory cycles, menstrual irregularity, sub-fertility, decreased oestrogen and testosterone production), sexual impairment (diminished libido, erectile dysfunction, retrograde or painful ejaculation, orgasmic dysfunction), breast abnormalities (breast enlargement, galactorrhoea) and bone impairment (decreased bone mineral density and osteoporosis).…”

Section: Introductionmentioning

confidence: 99%

Antipsychotics-related hyperprolactinaemia among patients with schizophrenia in Maiduguri

Shettima,

Wakil,

Sheikh

et al. 2024

South African Journal of Psychiatry

View full text Add to dashboard Cite

Background: Hyperprolactinaemia among patients on antipsychotic medications is generally overlooked due to lack of outwardly visible symptoms, patient resistance to reporting because the symptoms are perceived as shameful, or to clinician’s insufficient knowledge.Aim: The study aimed to evaluate the patterns and correlates of hyperprolactinemia among patients with schizophrenia on antipsychotic medications.Setting: The study was conducted in a psychiatric facility in Maiduguri, Northeastern Nigeria.Methods: A total of 209 patients with schizophrenia were evaluated through a cross-sectional design and assayed for serum prolactin with ELISA Kits. Frequencies and percentages were tabulated for categorical variables. Variables with significant associations with hyperprolactinaemia on chi-square (p 0.05) were subjected to logistic regression analysis.Results: The prevalence of hyperprolactinaemia was 45.9% in all patients on antipsychotic medication. The prevalence because of the use of typical and atypical antipsychotics was 51.5% and 25.0%, respectively. Hyperprolactinaemia was significantly associated with typical antipsychotics (β = 0314, p = 0.002), high overall drug dosage (β = 2.340, p = 0.003), high-dose typical antipsychotics (β = 3.228, p = 0.000), twice daily dosing frequency (β = 2.751, p = 0.001) and polypharmacy (β = 1.828, p = 0.0024).Conclusion: The findings support that patients on typical, high-dose antipsychotic medications and polypharmacy have a high prevalence of hyperprolactinaemia. As hyperprolactinaemia is often undetectable, screening and patient psycho-education on the significance of the signs and symptoms of hyperprolactinaemia is required for necessary clinical intervention.Contribution: The study provides evidence for the rational use of antipsychotic medications in sub-Saharan Africa.

show abstract

Correlation Between Prolactin and Symptom Profile in Acute Admitted Women With Recurrent Schizophrenia

Cited by 6 publications

References 12 publications

Improving treatment of women with schizophrenia: a review of the recent literature

Improving treatment of women with schizophrenia: a review of the recent literature

Depression and anxiety mediate the relationship between the retrospectively measured symptoms of premenstrual disorders and negative but not positive psychotic-like experiences

Antipsychotics-related hyperprolactinaemia among patients with schizophrenia in Maiduguri

Contact Info

Product

Resources

About